GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relief Therapeutics Holding SA (OTCPK:RLFTF) » Definitions » Forward PE Ratio

Relief Therapeutics Holding (Relief Therapeutics Holding) Forward PE Ratio : 0.00 (As of May. 12, 2024)


View and export this data going back to 1990. Start your Free Trial

What is Relief Therapeutics Holding Forward PE Ratio?

Relief Therapeutics Holding's Forward PE Ratio for today is 0.00.

Relief Therapeutics Holding's PE Ratio without NRI for today is 0.00.

Relief Therapeutics Holding's PE Ratio for today is 0.00.


Relief Therapeutics Holding Forward PE Ratio Historical Data

The historical data trend for Relief Therapeutics Holding's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relief Therapeutics Holding Forward PE Ratio Chart

Relief Therapeutics Holding Annual Data
Trend 2021-12 2022-02
Forward PE Ratio
1.12 1.30

Relief Therapeutics Holding Semi-Annual Data
2021-09 2021-12
Forward PE Ratio 2.13 1.12

Competitive Comparison of Relief Therapeutics Holding's Forward PE Ratio

For the Biotechnology subindustry, Relief Therapeutics Holding's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Relief Therapeutics Holding's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Relief Therapeutics Holding's Forward PE Ratio falls into.



Relief Therapeutics Holding Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Relief Therapeutics Holding  (OTCPK:RLFTF) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Relief Therapeutics Holding Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Relief Therapeutics Holding's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Relief Therapeutics Holding (Relief Therapeutics Holding) Business Description

Traded in Other Exchanges
Address
Avenue de Secheron 15, Fondation EIP, Batiment, Geneva, CHE, CH-1202
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Geographically group generates the majority of its revenue from Europe.

Relief Therapeutics Holding (Relief Therapeutics Holding) Headlines